Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) CEO Ivana Magovcevic-Liebisch bought 4,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $3.75 per share, with a total value of $15,000.00. Following the purchase, the chief executive officer now owns 207,687 shares of the company’s stock, valued at $778,826.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Vigil Neuroscience Trading Down 8.8 %
VIGL traded down $0.35 during trading on Monday, reaching $3.65. The stock had a trading volume of 708,860 shares, compared to its average volume of 52,843. The stock’s 50 day moving average is $6.34 and its two-hundred day moving average is $7.61. The company has a market capitalization of $130.95 million, a price-to-earnings ratio of -1.79 and a beta of 2.78. Vigil Neuroscience, Inc. has a one year low of $3.60 and a one year high of $13.55.
Hedge Funds Weigh In On Vigil Neuroscience
A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada bought a new position in shares of Vigil Neuroscience during the second quarter valued at $33,000. California State Teachers Retirement System bought a new position in shares of Vigil Neuroscience during the second quarter valued at $50,000. Wells Fargo & Company MN increased its holdings in shares of Vigil Neuroscience by 6,988.4% during the second quarter. Wells Fargo & Company MN now owns 6,096 shares of the company’s stock valued at $57,000 after acquiring an additional 6,010 shares in the last quarter. American International Group Inc. bought a new stake in Vigil Neuroscience in the 2nd quarter worth about $73,000. Finally, Morgan Stanley increased its holdings in Vigil Neuroscience by 6,893.8% in the 4th quarter. Morgan Stanley now owns 9,092 shares of the company’s stock worth $114,000 after buying an additional 8,962 shares in the last quarter. Institutional investors own 71.80% of the company’s stock.
Analyst Upgrades and Downgrades
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
- Five stocks we like better than Vigil Neuroscience
- How to Invest in the Entertainment Industry
- The most upgraded stocks in November have two things in common
- Insider Trading – What You Need to Know
- Monday.com rocked earnings like it’s the weekend
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.